Longeveron (LGVN) EBIT Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBIT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -1,651.00 |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -44,226.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44,226.00 |
| Mar 31, 2026 | 16,009.00 |
| Dec 31, 2025 | -76,923.00 |
| Sep 30, 2025 | -473,434.00 |
| Jun 30, 2025 | -96,005.00 |
| Mar 31, 2025 | -61,349.00 |
| Dec 31, 2024 | 792,497.00 |
| Sep 30, 2024 | 283,924.00 |
| Jun 30, 2024 | 188,439.00 |
| Mar 31, 2024 | 94,397.00 |
| Dec 31, 2023 | -430,352.00 |
| Sep 30, 2023 | 174,633.00 |
| Jun 30, 2023 | -172,646.00 |
| Mar 31, 2023 | -59,548.00 |
| Dec 31, 2022 | -240,222.00 |
| Sep 30, 2022 | -307,278.00 |
| Jun 30, 2022 | 12,938.00 |
| Mar 31, 2022 | -17,516.00 |
| Sep 30, 2021 | -206,286.00 |
| Jun 30, 2021 | -62,651.00 |